Read by QxMD icon Read

European Journal of Cancer & Clinical Oncology

B A Stoll
We must still maintain the conventional advice that unopposed low dosages of oestrogen should not be used for the treatment of menopausal symptoms in women treated previously for breast cancer. There is, however, epidemiological, laboratory and clinical evidence that certain combinations of oestrogen and progestagen are more likely to be beneficial than harmful, in respect to the risk of reactivating subclinical residual breast cancer or causing progression in premalignant lesions. It is no longer justifiable to deprive a woman with a history of breast cancer treatment of a hormonal therapy capable of safely relieving symptoms which are making her life intolerable...
December 1989: European Journal of Cancer & Clinical Oncology
G R Weiss, G A Sarosy, T D Shenkenberg, T Williams, N J Clendeninn, D D Von Hoff, J L Woolley, S H Liao, M R Blum
Thirty-eight patients with advanced resistant cancers were enrolled on this study of piritrexim (PTX; BW 301U) administered intravenously weekly for 4 weeks. Of 50 courses of treatment begun, 39 evaluable 4-week courses of the drug were completed by this group of patients. Dosages ranged from 44 to 530 mg/m2/week. One patient at each dosage level received an initial weekly dose of PTX in oral form accompanied by pharmacokinetic blood sampling after the oral dose and also after a subsequent intravenous dose...
December 1989: European Journal of Cancer & Clinical Oncology
D Schuster, M E Heim, G Decoster, W Queisser
Doxifluridine, a new fluoropyrimidine analog, was administered to 21 patients with advanced colorectal carcinoma. The starting dose was 1.0 g/m2 given over 24 h for 90 consecutive days as a continuous infusion. Due to severe skin reactions (hand-foot syndrome), the dose was reduced stepwise to 0.75 g/m2/day. Twenty patients were evaluable for efficacy, one had an early non-toxic death. Seven out of 20 (35%) showed a partial response; disease stabilization was observed in 10 patients (50%) and three showed progressive disease after 3 months of treatment...
November 1989: European Journal of Cancer & Clinical Oncology
J D Meyers
Viral infections are of increasing importance in the compromised host, particularly herpesvirus infections. Both intravenous and oral acyclovir are effective in preventing reactivation of herpes simplex virus infection; oral regimens are less expensive but compliance may be problematic. Varicella zoster virus reactivation can be suppressed for 6-12 months after marrow transplant using oral acyclovir, although infection may occur at the usual rate when prophylaxis is stopped. Intravenous acyclovir given for 30 days after marrow transplant reduced cytomegalovirus disease by 50%...
September 1989: European Journal of Cancer & Clinical Oncology
P Alberto, J J Winkelmann, N Paschoud, R Peytremann, A Bruyere, A Righetti, G Decoster, E E Holdener
No abstract text is available yet for this article.
May 1989: European Journal of Cancer & Clinical Oncology
R H Liang, E K Woo, Y L Yu, D Todd, T K Chan, F C Ho, S C Tso, J S Shum
Fifty-eight Hong Kong Chinese patients with CNS lymphoma were reviewed (primary seven, secondary 51). The incidence of secondary CNS lymphoma in patients with non-Hodgkin's lymphoma was estimated to be 9.4%. The Working Formulation separated subtypes which had a special propensity to involve the CNS. Significant proportions of our patients with secondary CNS lymphoma had other features which were known to be associated with a high risk of CNS disease including stage IV (48/51, 91.4%), bone marrow (26/51, 50...
April 1989: European Journal of Cancer & Clinical Oncology
R N Smith
The safety of ondansetron has been reviewed based on experience in its use as an anti-emetic treatment in about 1,400 patients receiving cancer treatment and further experience in about 650 volunteers and patients with other medical conditions. Evidence from animal pharmacology and toxicology had indicated that ondansetron had a wide therapeutic index, no interaction with commonly co-prescribed drugs, and no dependence liability. No end-organ toxicity had been seen. Clinical experience showed that ondansetron is well tolerated; the principal side effects being constipation and headache, which in the context of cancer treatment were not troublesome...
1989: European Journal of Cancer & Clinical Oncology
T J Priestman
Ondansetron is a 5-HT3 receptor antagonist which has shown activity in the prevention of nausea and vomiting resulting from cytotoxic therapy. This paper describes the results of studies evaluating the efficacy of oral ondansetron in controlling radiation-induced emesis. Initial non-randomised studies showed that doses of 4 mg q.d.s. or 8 mg t.d.s. of ondansetron achieved complete or major control of vomiting in 77-91% of patients and mild or absence of nausea in 72-77% following single exposure high-dose (8-10 Gy) radiotherapy to the upper abdomen...
1989: European Journal of Cancer & Clinical Oncology
B Lathan, V Diehl, G M Clark, D D von Hoff
A human tumor cloning system was utilized to screen for in vitro antitumor effects of the new purine antimetabolite 9-beta-D-arabinofuranosyl-2-fluoroadenine 5-monophosphate. Two hundred and thirty-one specimens were evaluable for drug sensitivity information (i.e. greater than or equal to 20 colonies on control plates). The overall in vitro response rates (defined as a less than or equal to 50% survival of tumor colony forming units) at two different concentrations of the new drug (0.1; 1.0 micrograms/ml) were between 21 and 24%...
December 1988: European Journal of Cancer & Clinical Oncology
M A Piens, D Guyotat, E Archimbaud, C Plotton, J Maupas, M Mojon, D Fiere
The diagnostic efficiency of a serum Candida antigen detection test Cand-Tec test) was prospectively investigated in 104 leukemic patients treated by intensive chemotherapy or allogeneic bone marrow transplantation. Candida antigen titers were determined on admission and then weekly as long as patients remained neutropenic. Nine patients had a proven disseminated yeast infection (diagnosed only at autopsy in five cases). The highest Candida antigen titers were 1:2 in two patients and 1:4 or more in seven patients (sensitivity: 76% for this last titer)...
October 1988: European Journal of Cancer & Clinical Oncology
A Azzarelli, V Mazzaferro, V Quagliuolo, R A Audisio, G Colella, G Bandieramonte, G Dossena, L Gennari
UNLABELLED: In order to provide information on the response to treatments and clinico-pathological pattern, the clinical course of 41 patients with classic Kaposi's sarcoma (KS) was reconsidered. Twenty-six cases presented a single nodular lesion, and 15 multiple, pluricentric lesions. Surgery was the first treatment for patients with single lesions, 14 of 26 (54%) patients had recurrences: the disease-free interval ranged from a few months to 11 years. Five cases had disseminated disease, three of these were preceded by local recurrence...
June 1988: European Journal of Cancer & Clinical Oncology
P Alberto, W F Jungi, P Siegenthaler, B Mermillod, J P Obrecht, G Decoster, F Cavalli
No abstract text is available yet for this article.
March 1988: European Journal of Cancer & Clinical Oncology
P Alberto, B Mermillod, G Germano, S Kaplan, W Weber, R Joss, B Spati, G Martz, F Cavalli
In a randomized study 52 patients with advanced colorectal cancer and measurable lesions were treated with doxifluridine 4000 mg/m2 or fluorouracil 450 mg/m2 i.v. on 5 consecutive days over 3 weeks. None had prior fluoropyrimidines except two who received adjuvant fluorouracil. Partial responses with a duration ranging from 259 to 406 days were observed in five patients treated with doxifluridine and two patients treated with fluorouracil. Toxic reactions were evaluated in 88 doxifluridine courses and 105 fluorouracil courses...
March 1988: European Journal of Cancer & Clinical Oncology
P H Willemse, L D Dikkeschei, N H Mulder, E van der Ploeg, D T Sleijfer, E G de Vries
A phase II study with cyproterone acetate (CPA) was done as the primary treatment in female breast cancer patients. Twenty-three patients, mean age 64 years, range 52-75 years, were entered and treated with CPA 400 mg daily. Twenty patients were evaluable and responses were sparse. There was one partial and one complete remission, 17 patients were stable and one patient progressed within 3 months. Side-effects were frequent: five patients complained of nausea, three had severe weight loss, one suffered from depression and seven showed disturbed liver function tests...
March 1988: European Journal of Cancer & Clinical Oncology
R Abele, M Clavel, P Dodion, U Bruntsch, S Gundersen, J Smyth, J Renard, M van Glabbeke, H M Pinedo
The Early Clinical Trials Cooperative Group of the EORTC conducted several phase II studies with a pyrimidine analogue of deoxycytidine, 5-aza-2'-deoxycytidine (DAC). The drug was given as three consecutive 1 h i.v. infusions of 75 mg/m2, separated by intervals of 7 h; courses were repeated every 5 weeks. A total of 101 eligible patients were studied: 42 with colo-rectal adenocarcinoma, 27 with squamous cell carcinoma of the head and neck, 18 with malignant melanoma and 14 with renal cell carcinoma. Drug-induced toxicities consisted of moderate myelosuppression, and nausea and vomiting...
December 1987: European Journal of Cancer & Clinical Oncology
N K Ahmed, G Vasanthakumar
Daunorubicin (D1)-resistant cells have been isolated from daunorubicin reductase-deficient K562 cells, hence, metabolism of D1 to the alcohol metabolite daunorubicinol (D2) will not contribute to the development of resistance. The resistant cell lines were 22-123-fold resistant and were cross-resistant to a variety of drugs. Drug uptake and efflux were altered in the more resistant lines but not in the less resistant cells. Verapamil enhanced D1 cytotoxicity in all resistant lines; it inhibited D1 efflux in the higher resistant line thereby resulting in an increase in the cellular level of D1...
September 1987: European Journal of Cancer & Clinical Oncology
S W Lamberts, T Verleun
Chronic administration of the catecholestrogens 2-OH-estrone (2-OH1) and 2-OH-estradiol (2-OHE2), of tamoxifen and its metabolites and of high concentrations of estradiol have been previously shown to inhibit the growth of the estrogen/progesterone receptor-positive transplantable prolactin (PRL)-secreting rat pituitary tumor 7315a. The mechanism of action of these inhibitory effects on tumor growth is unknown. In the present study we investigated the direct effects of these compounds on PRL release by a tumor cell clone derived from the 7315a tumor...
August 1987: European Journal of Cancer & Clinical Oncology
M Stroun, P Anker, J Lyautey, C Lederrey, P A Maurice
UNLABELLED: Ten out of 37 patients with advanced malignant diseases were found to have extractable amounts of DNA in their plasma whereas no DNA could be detected in 50 normal controls. After its purification from the original nucleoprotein complex, DNA plasma levels ranging from 0.15 to 12 micrograms/ml were measured, the lowest concentration detectable with our method being 0.1 microgram/ml. Knowing from recovery experiments performed with 32P-DNA that the loss of DNA during the extraction procedure is about 65%, the real concentration of DNA in the plasma corresponds to about 3 times the given figures...
June 1987: European Journal of Cancer & Clinical Oncology
G Schwartsmann, H M Pinedo, A Leyva
Two sublines of HL-60 cells differing markedly in their ability to undergo differentiation to granulocytes after treatment with retinoic acid (RA), dimethyl sulfoxide (DMSO) and the pyrimidine analog, 5-aza-2'-deoxycytidine (azadCyd) were studied. The sensitive subline (HL-60 S) responded well to 1 microM RA, 1% DMSO and 1 microM azadCyd, showing 89 +/- 5%, 46 +/- 5% and 29 +/- 6% mature nitroblue tetrazolium (NBT)-positive cells, respectively. However, the resistant subline (HL-60 R) showed only modest maturational effects (12 +/- 3%, 11 +/- 2% and 9 +/- 2%, respectively) after treatment with the same agents...
June 1987: European Journal of Cancer & Clinical Oncology
F R Appelbaum, E D Thomas
No abstract text is available yet for this article.
March 1987: European Journal of Cancer & Clinical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"